Retinal biologics companies focus on the development and commercialization of biopharmaceuticals designed to treat retinal disorders. These disorders often affect the retina, a critical part of the eye responsible for capturing and processing light signals.
Regeneron Pharmaceuticals (US) Received FDA approval for the expanded use of EYLEA® (aflibercept) for the treatment of diabetic macular edema (DME) with persistent center-point fluid after prior anti-VEGF therapy. Partnered with research institutions to develop next-generation retinal biologics targeting multiple pathways for improved disease management.
Roche (Switzerland) Announced positive Phase III results for their FARICIMAB (VABY88A), demonstrating its non-inferiority to aflibercept in treating wet AMD. Collaborated with healthcare providers to expand access to retinal biologics treatments and improve patient outcomes.
Genentech (US) Launched their LUCENTIS® (ranibizumab) prefilled syringe for DME and wet AMD, offering enhanced convenience for both patients and healthcare professionals. Focused on developing long-acting biologics, potentially reducing the frequency of injections and improving patient compliance.
Novartis (Switzerland) Received FDA approval for their Beovu® (brolucizumab) for the treatment of wet AMD, offering extended dosing intervals compared to other anti-VEGF drugs. Partnered with ophthalmic societies to provide educational resources and training programs on the use of retinal biologics in clinical practice.
American Academy of Ophthalmology (AAO)Â Updated their guidelines for the management of wet AMD and DME, highlighting the role of retinal biologics as primary treatment options. Launched initiatives to advocate for improved access to these therapies and promote patient education about retinal diseases.
Retinal Biologics Market Size was valued at USD 6.5 Billion in 2022. The Retinal Biologics market Drug Class is projected to grow from USD 7.4 Billion in 2023 to USD 19.8 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 13.20% during the forecast period (2023 - 2032). Retinal vein occlusion (RVO) and age-related macular degeneration are becoming more common, and there are a rising number of cases of ophthalmic conditions causing chronic retinal diseases worldwide, are the key market drivers enhancing the market growth.
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
The main reason fueling the market's expansion is the rising incidence of ocular problems that lead to chronic retinal diseases in different parts of the world. The World Health Organisation estimates that over 2.2 billion individuals worldwide have a vision issue. The enormous patient base experiencing eye problems is what fuels market expansion. Age-related macular degeneration (AMD) and retinal vein occlusion (RVO) are becoming more common. RVO is the second most prevalent retinal vascular condition and a major contributor to vision loss. There are around 11 million Americans who suffer from some sort of age-related macular degeneration. By 2050, this figure is projected to rise to around 22 million. The market expansion for retinal biologics is supported over the forecast period by expanding R&D efforts and new launches.
The market would be propelled by a high emphasis on research and development (R&D) related to retinal gene treatments carried out by various institutes, biologics companies, and innovative product releases by key industry participants in the form of biologics and implants. The market will grow faster if efforts are made to provide complementary therapeutic interventions. Concern over diabetic retinopathy has increased as more type I and type II adult diabetes individuals experience visual loss as a result of the condition. The effects of diabetic retinopathy, which cause the macula to swell, also result in diabetic macular edoema. Another factor driving the demand for retinal medicines and biologics is the rising prevalence of other retinal illnesses such uveitis and orbital inflammation. Retinal gene therapy is a therapeutic strategy in which DNA or RNA is used to treat inherited faulty genes. Because there is minimal contamination and the viral vector can fit easily into the eyes, retinal gene therapy is seen as a key strategy.
Age-related macular degeneration (AMD) and other disorders associated with an ageing population will be a driving force behind this market's expansion. There are about 15 million AMD sufferers in the United States, according to studies by the American Academy of Ophthalmology. In some persons, especially the elderly, the condition may result in a loss of central visual acuity in either one or both eyes. Age-related progression of AMD disease puts the older population at higher risk. Additionally, increased alcohol and smoking use opens the door for a number of illnesses, including hypertension and hypercholesterolemia, which will benefit the retinal biologics business. The development of retinal biologics will benefit from significant investments in R&D as well as strategic alliances amongst market participants. As diabetes causes diabetic retinopathy and diabetic macula edoema, two of the most prevalent retinal illnesses, it will also have an impact on the growth of the retinal biologics market. Thus, driving the Retinal Biologics market revenue.
The  Retinal Biologics market segmentation, based on Drug Class, includes TNF-a inhibitor and VEGF-A antagonist. VEGF-A antagonist segment dominated the  market in 2022. This biologic is used to treat age-related macular degeneration with neovascularization. Businesses are concentrating on creating and introducing VEGF for the treatment of eye issues. For instance, Lucentis (ranibizumab injectable) for the treatment of diabetic retinopathy was approved by the US FDA in March 2018 and was manufactured by F. Hoffmann-La Roche Ltd. The segmented retinal biologics market is expanding as a result of rising product approvals and the introduction of new treatments.
The  Retinal Biologics market segmentation, based on Indication, includes macular degeneration, diabetic retinopathy, uveitis, and others. Macular degeneration segment dominated the  market in 2022. One of the main causes of the  incidence of DR is the rapidly growing diabetic population. By 2045, the International Diabetes Federation (IDF) predicts that 783 million adults would be living with diabetes. As a result, it could raise the risk of DR, which is one of the most prevalent reasons for visual loss in people with diabetes. These elements are anticipated to hasten the market development for retinal biologics.
The  Retinal Biologics market segmentation, based on Distribution Channel, includes hospitals and clinics, pharmacies, and others. Hospitals and clinics segment dominated the  Retinal Biologics market in 2022. Hospitals have access to a wide variety of cutting-edge treatments that can significantly improve a patient's surgical success. Retinal biologic treatments have been made available by numerous prestigious hospital networks to successfully treat a range of eye conditions. As an illustration, the Max Hospital in South Delhi, India opened its Max Institute Eye Care (MIEC), a cutting-edge eye care facility, to provide cutting-edge technologies and treatments for various eye illnesses. Such advancements are enhancing the market outlook by enticing more patients to visit hospitals for routine eye exams.
Figure 1 Â Retinal Biologics Market, by Distribution Channel, 2022 & 2032 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Retinal Biologics Regional Insights
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Retinal Biologics Market dominated this market in 2022 (45.80%). Eye illnesses are regarded as one of the ongoing issues for the US and other nations. Due to the increasing incidences of macular degeneration, diabetic retinopathy, uveitis, and other eye diseases, America accounted for the largest market. Macular degeneration affects about 196 million individuals ly today, and that number is predicted to rise to 288 million by 2040. The need for retinal biologics products is rising in this region as there are more and more new cases of eye ailments. Further, the U.S. Retinal Biologics market held the largest market share, and the Canada Retinal Biologics market was the fastest growing market in the North America region.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2 Â RETINAL BIOLOGICS MARKET SHARE BY REGION 2022 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Retinal Biologics market accounted for the healthy market share in 2022. Growing healthcare innovation, increased emphasis on creating new retinal biologics, and the presence of numerous healthcare businesses in this area all contribute to the expansion of the European market. In the European Union (EU) and its five most populous nations—Germany, France, the United Kingdom, Italy, and Spain—almost 22 million individuals had age-related macular degeneration (AMD) as of 2017. Further, the German Retinal Biologics market held the largest market share, and the U.K Retinal Biologics market was the fastest growing market in the European region
The Asia Pacific Retinal Biologics market is expected to register significant growth from 2023 to 2032. Due to increased research into the creation of retinal biologics and the rising incidence of eye illnesses, this region has been experiencing an increase in market growth. Additionally, the market for retinal biologics is supported by the growing elderly population. Moreover, China’s Retinal Biologics market held the largest market share, and the Indian Retinal Biologics market was the fastest growing market in the Asia-Pacific region.
Retinal Biologics Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Retinal Biologics market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Retinal Biologics Industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  Retinal Biologics Industry to benefit clients and increase the market sector. In recent years, the Retinal Biologics Industry has offered some of the most significant advantages to medicine. Major players in the Retinal Biologics market, including Amgen, Inc., AbbVie Inc., MeiraGTX Limited, Regeneron Pharmaceuticals Inc, Ocular Therapeutixc., Spark Therapeutics, F. Hoffmann-La, Roche Ltd., Genentech, and Johnson & Johnson, are attempting to increase market demand by investing in research and development operations.
A biotechnology corporation called F. Hoffmann-La Roche Ltd. (Roche) creates medications and diagnostic tools to combat serious illnesses. It offers medications for the treatment of respiratory illnesses, cancer, various auto-immune diseases, neurological disorders, ophthalmological disorders, and central nervous system problems. The business also provides diabetes management programmes, tissue-based cancer diagnostics, and in vitro diagnostics. Roche carries out research to find cutting-edge ways to treat, diagnose, and prevent illnesses. Hospitals, healthcare professionals, commercial laboratories, researchers, and chemists are among the groups that the business serves with its goods and services. In order to increase SemaThera's portfolio of innovative biologics for the treatment of ischemic retinal diseases such diabetic retinopathy, Roche and SemaThera Inc. launched a multi-year research and licencing collaboration in 2021.
The creation, manufacture, and marketing of prescription and over-the-counter medications, as well as items for eye care, are the specialties of a healthcare company by the name of Novartis AG (Novartis). It provides medications for treating solid tumours, immune system problems, infections, cardiovascular disease, dermatological problems, neurological problems, ophthalmic and respiratory illnesses, cancer, and neurological abnormalities, among other conditions. The company sells biosimilars and generic drugs through Sandoz. Novartis conducts research in several disease-related sectors through the Novartis Institutes for BioMedical Research (NIBR). Novartis' supplementary biologic licence application (sBLA) for Beovu (brolucizumab) 6 mg for the treatment of diabetic macular edoema (DME) was approved by the US Food and Drug Administration (FDA) in October 2021.
Key Companies in the Retinal Biologics market include
Retinal Biologics Industry Developments
July 2021Â The Biologics Licence Application (BLA) for faricimab by Genentech to treat wet, or neovascular, diabetic macular edoema (DME), age-related macular degeneration (AMD), and diabetic retinopathy has been authorised by the US Food and Drug Administration (FDA). Genentech is a part of the Roche Group.
Retinal Biologics Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)